Screener
Core Laboratories CLB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Core Laboratories in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Core Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 6:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-198109
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $22,819 | $22,702 |
| Accounts receivable, net of allowance for credit losses of $6,488 and $6,317 at 2026 and 2025, respectively | 108,277 | 113,528 |
| Inventories | 57,784 | 54,496 |
| Prepaid expenses | 11,356 | 9,734 |
| Income taxes receivable | 6,917 | 7,270 |
Item 1. Financial Statements
FAQ
- What is Core Laboratories's cash & equivalents?
- Core Laboratories (CLB) reported cash & equivalents of $22.82M in Q1 2026.
- How has Core Laboratories's cash & equivalents changed year-over-year?
- Core Laboratories's cash & equivalents increased by 3.2% year-over-year, from $22.11M to $22.82M.
- What is the long-term trend for Core Laboratories's cash & equivalents?
- Over 3 years (2022 to 2025), Core Laboratories's cash & equivalents has grown at a 13.7% compound annual growth rate (CAGR), from $15.43M to $22.7M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Core Laboratories's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude